Pathogenesis of cholestatic itch: Old questions, new answers, and future opportunities

Hepatology

Volumn 56, Issue 4, 2012, Pages 1194-1196

  Jones, David E J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOTAXIN; BILE ACID; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; PREGNANE X RECEPTOR; RIFAMPICIN;

CHOLESTASIS; CHOLESTATIC PRURITUS; DISEASE SEVERITY; EDITORIAL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PRURITUS;

CHOLESTASIS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; PHOSPHORIC DIESTER HYDROLASES; PRURITUS;

EID: 84867183340     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25847     Document Type: Editorial

References (19)

1. Poupon RE, Chretien Y, Chazouilleres O, Poupon R, Chwalow J. Quality of life in patients with primary biliary cirrhosis. HEPATOLOGY 2004; 40: 489-494.
2. Jones EA, Bergasa NV. The pruritus of cholestasis. HEPATOLOGY 1999; 29: 1003-1004.
3. Newton JL, Gibson JG, Tomlinson M, Wilton K, Jones DEJ. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. HEPATOLOGY 2006; 44: 91-98.
4. Beuers U, Boberg KM, Chazouilleres O, Jones DEJ, O'Invernizzi P, Lammert F, et al. EASL practice guidelines on management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267.
5. Prince MI, Burt AD, Jones DEJ. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50: 436-439.
6. McRae CA, Prince MI, Hudson M, Day CP, James OFW, Jones DEJ. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 2003; 125: 591-596.
7. Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1966; 50: 323-332.
8. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102: 544-549.
9. Kremer AE, Martens JJ, Kulik W, Rueff F, Kuiper EM, van Buuren HR, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010; 139: 1008-1018.
10. Ertel W, Kremer J-P, Kenney J, Steckholzer U, Jarrar D, Trentz O, et al. Downregulation of pro-inflammatory cytokine release in whole blood from septic patients. Blood 1995; 85: 1341-1347.
11. Nakanaga K, Hama K, Aoki J. Autotaxin-an LPA producing enzyme with diverse functions J Biochem 2010; 148: 13-24.
12. Kremer AE, van Dijk R, Leckie P, Schaap FG, Kuiper EMM, Mettang T, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions. HEPATOLOGY 2012; 56: 1391-1400.
13. Khurana S, Singh P. Rifampin is safe for the treatment of pruritus die to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 2006; 26: 943-948.
14. Leckie P, Tritto G, Mookerjee R, Davies N, Jones DEJ, Jalan R. "Out-patient" albumin dialysis for cholestatic patients with intractable itch. Aliment Pharmacol Ther 2012; 35: 696-704.
15. Albers HMHG, Dong A, van Meeteren LA, Egan DA, Sunkara M, van Tilburg EW, et al. Boronic acid-based inhibitor of autotaxin revelas rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A 2010; 107: 7257-7262.
16. Nikitopoulou I, Oikonomou N, Karouzakis E, Sevastou I, Nikloaidou-Katsaridou N, Zhao Z, et al. Autotaxin expression form synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med 2012; 209: 925-933.
17. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3: 582-591.
18. Jones DEJ. Pathogenesis of primary biliary cirrhosis. Gut 2007; 56: 1615-1624.
19. Sasaki M, Ikeda H, Haga H, Manabe T, Nakanuma Y. Frequent cellular senescence in small bile ducts in primary biliary cirrhosis: a possible role in bile duct loss. J Pathol 2005; 205: 451-459.